A budget impact analysis of the introduction of erythropoiesis stimulating agent subsequent entry biologics for the treatment of anemia of chronic kidney disease in Canada

Retrospective Study on the Influencing Factors and Prediction of Hospitalization Expenses for Chronic Renal Failure in China Based on Random Forest and LASSO Regression

Aim: With the improvement in people's living standards, the incidence of chronic renal failure (CRF) is increasing annually. The increase in the number of patients with CRF has significantly increased pressure on China's medical budget. Predicting hospitalization expenses for CRF can provide guidance for effective allocation and control of medical costs. The purpose of this study was to use the random forest (RF) method and least absolute shrinkage and selection operator (LASSO) regression to predict personal hospitalization expenses of hospitalized patients with CRF and to evaluate related influencing factors.

Methods: The data set was collected from the first page of data of the medical records of three tertiary first-class hospitals for the whole year of 2016. Factors influencing hospitalization expenses for CRF were analyzed. Random forest and least absolute shrinkage and selection operator regression models were used to establish a prediction model for the hospitalization expenses of patients with CRF, and comparisons and evaluations were carried out.

Results: For CRF inpatients, statistically significant differences in hospitalization expenses were found for major procedures, medical payment method, hospitalization frequency, length of stay, number of other diagnoses, and number of procedures. The R² of LASSO regression model and RF regression model are 0.6992 and 0.7946, respectively. The mean absolute error (MAE) and root mean square error (RMSE) of the LASSO regression model were 0.0268 and 0.043, respectively, and the MAE and RMSE of the RF prediction model were 0.0171 and 0.0355, respectively. In the RF model, and the weight of length of stay was the highest (0.730).

Conclusions: The hospitalization expenses of patients with CRF are most affected by length of stay. The RF prediction model is superior to the LASSO regression model and can be used to predict the hospitalization expenses of patients with CRF. Health administration departments may consider formulating accurate individualized hospitalization expense reimbursement mechanisms accordingly.

Economic Evaluation of Severe Anaemia: Review-Based Recommendations and a Conceptual Framework

Objective: Novel anaemia treatments have greatly improved patient outcomes in the last decade and have also undergone economic evaluations in various settings using heterogenous model structures, costs, and inputs. The objectives were to review published economic evaluation studies in major red blood cell disorders, identify limitations in the applied methodology, provide a set of recommendations, and produce a conceptual framework for future economic research in this disease area. Methods: A targeted search was conducted for economic literature evaluating treatments in major red blood cell disorders related to anaemia. Disorders included autoimmune haemolytic anaemia, β-thalassaemia, chemotherapy-induced anaemia, anaemia in chronic kidney disease, and severe aplastic anaemia. Budget impact models and cost-effectiveness and cost-utility analyses were considered. Modelling assumptions regarding the model structure, time horizon, perspective, and type of costs were reviewed and recommendations and a conceptual framework for future economic analyses were created. Results: A total of four budget impact models, nine cost-utility analyses, and four cost-effectiveness analyses were investigated. A major limitation was that the included costs varied significantly across studies. Costs which were rarely included, and generally should be considered, were related to adverse events, mortality, and productivity. Additionally, relationships between levels of serum ferritin, hepatic or total body iron, and haemoglobin with long-term complications and mortality were rarely included. Conclusion: Published economic analyses evaluating treatments for major red blood cell disorders frequently exclude vital costs. A set of recommendations and a conceptual framework will aid researchers in applying a more comprehensive approach for economic evaluations in major red blood cell disorders.

Biosimilars to recombinant human FSH medicines: comparable efficacy and safety to the original biologic

Two recombinant follicle-stimulating hormone (rFSH)-bearing similar biological medicines (biosimilars) have been authorized by the European Commission. Biosimilar is a regulatory concept alluding to the evidence-based high-standard comparability studies needed to demonstrate its equivalence to a reference original biologic. Because biosimilar development represents a shift from the long-lasting existing paradigms, a thorough understanding of the science behind it will contribute to helping prescribers make informed treatment choices. Contrary to chemically-synthesized medicines, biologics are subject to an inherent molecular variability. From the experience with original biologics, regulatory authorities have accumulated a wealth of knowledge as to what minor batch-to-batch physicochemical variations may be therapeutically acceptable in a given product. Furthermore, in spite of analytically detectable differences, the two original rFSH-bearing medicines currently on the market share fundamentally the same therapeutic profile. Unlike those original medicines, a biosimilar of an rFSH product and the corresponding reference biologic share essentially the same active pharmaceutical ingredient. They are also administered via the same route, at the same dose, and for the same indications. This article revises the background evidence over which the biosimilarity principle has been built, and highlights the therapeutic potential for follitropin biosimilars in order to reassure physicians on their benefit.

Efficacy and safety data of subsequent entry biologics pertinent to nephrology practice: a systematic review

Background

Subsequent entry biologics (SEBs) may soon be a reality in Canadian nephrology practice. Understanding the worldwide experience with these agents will be valuable to Canadian clinicians.

Objectives

To compare the efficacy and safety data between SEBs used in nephrology practice and their reference biologic.

Design

Systematic review.

Sources of information

Ovid MEDLINE, EMBASE, Cochrane Database of Systematic Reviews, Database of Abstracts of Review of Effects, Cochrane Central Register of Controlled Trials.

Patients

Adult patients with chronic kidney disease (CKD).

Methods

Our systematic review follows the process outlined by Cochrane Reviews. For efficacy data, all randomized controlled trials (RCTs), quasi-RCTs and observational trials in nephrology practice were included. For safety data, case series, case reports, review articles in nephrology practice and pharmacovigilance programs were included as well.

Results

Only epoetin SEBs trials were published in the literature. Ten studies involving three different epoetin SEBs (epoetin zeta, HX575 and epoetin theta) were included. The mean epoetin dose used did not differ significantly between the SEBs and the reference product. For epoetin zeta and epoetin theta, the mean hemoglobin levels achieved in the studies were similar between the SEBs and the reference epoetin. The HX 575 studies reported a mean absolute change in hemoglobin within the predefined equivalence margin, when compared with the reference biologic. In terms of safety data, 2 cases of pure-red-cell aplasia were linked to the subcutaneous administration of HX 575. Otherwise, the rate of adverse drug reactions was similar when epoetin SEBs were compared with the reference biologic.

Limitations

Our analysis is limited by the paucity of information available on SEB use in nephrology with the exception of epoetin SEBs. Methodological flaw was found in one of the epoetin zeta studies which accounted for 45% of pooled results.

Conclusions

Little clinical difference was found between epoetin SEBs and the reference product. Although not deemed clinically important, the financial implication of a possible dose difference between epoetin zeta and reference product should be considered in pharmacoeconomic studies. Ongoing trials are expected to address the risk of pure-red-cell aplasia with HX 575.